stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +27.0%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Debt to equity
LivaNova PLC's debt to equity at the end of the quarter to 30 September 2026 was 0.2×, down 0.1× from fiscal 2025 (0.3×). Over the past ten years it has ranged from 0.0× (fiscal 2015) to 0.6× (fiscal 2020); the current reading is higher than 67% of that period. That is above the Medical Devices industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.3× | (33.97%) |
| FY2024 | 0.5× | 3.53% |
| FY2023 | 0.5× | 2.41% |
| FY2022 | 0.4× | 142.38% |
| FY2021 | 0.2× | (68.70%) |
| FY2020 | 0.6× | 142.15% |
| FY2019 | 0.2× | 118.14% |
| FY2018 | 0.1× | 39.18% |
| FY2017 | 0.1× | 11.67% |
| FY2016 | 0.1× | (25.16%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.2× | (1.54%) |
| Jun 2026 | 0.2× | (6.82%) |
| Mar 2026 | 0.2× | (24.31%) |
| Dec 2025 | 0.3× | (16.38%) |
| 44 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| TXG 10x Genomics compare | 0.0× |
| AXGN AxoGen, Inc. compare | 0.0× |
| BIO Bio-Rad Laboratories, Inc. compare | 0.2× |
| LIVN LivaNova PLC | 0.2× |
| NEOG Neogen Corporation compare | 0.4× |
| ITGR Integer Holdings Corporation compare | 0.7× |
| BRKR Bruker Corporation compare | 0.7× |
| HAE Haemonetics Corporation compare | 1.2× |
| IRTC iRhythm Holdings, Inc. compare | 3.7× |
| Medical Devices industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement